General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Targeted therapies

The importance of targeted therapies

We aim to ensure that the right patient is treated with the right dose of the right medicine at the right time. We believe that treatments should become targeted and based on an understanding of a patient’s unique genetic make up and individual response to a medicine.

Traditionally, medicines have been developed with a ‘one-size-fits-all’ model. Approximately half of all patients who take medicines do not respond to them, indicating that there is critical need for a more targeted approach to drug discovery and development.

Advances in biology and computer science are enabling unprecedented analysis of human genes and proteins. These advances help identify patients that may respond positively to particular therapies with new diagnostic tools.

We expect that, in the future, customized therapies and companion diagnostics will help physicians select medicines that have the greatest efficacy and the lowest probability of harmful side effects for individual patients.

Advancing customized therapies at Novartis

Our goal is to optimize patient outcomes by delivering targeted treatments.

By beginning to genetically identify patients who will respond positively to particular therapies, we are starting to tackle two of the greatest challenges in developing drugs: identifying a disease area with a critical, unmet need and assigning studies to test a clinical hypothesis.

Teams across Novartis work together to develop customized therapies for patients.